Few prostate cancer choices feel as weighty as this one. If you have been told that both robotic prostatectomy and radiotherapy are reasonable options, the difficult part is not finding a treatment — it is choosing the treatment whose trade-offs you can live with.
That matters because, for many men with localised or locally advanced prostate cancer, this is not a choice between a good option and a bad one. It is a choice between two strong treatments with different patterns of side effects, different recovery paths, and different practical demands on your daily life. The right answer is rarely the same for every patient.
For many men with prostate cancer that has not spread beyond the prostate, surgery and radiotherapy offer very similar long-term cancer control. The ProtecT trial — the largest UK randomised study comparing both treatments — found no meaningful difference in prostate cancer mortality at 10 years between surgery and radiotherapy in localised disease. So the decision often turns not on which treatment is "better", but on which one best fits your tumour, your health, your priorities, and what side effects matter most to you personally.
The key differences at a glance
| Treatment area | Robotic prostatectomy | External beam radiotherapy |
|---|---|---|
| What it involves | Keyhole surgery to remove the prostate — one procedure, general anaesthetic | Outpatient treatment over several weeks, no operation |
| Cancer control | Excellent for localised disease — equivalent to radiotherapy in most risk groups | Excellent for localised disease — equivalent to surgery in most risk groups |
| Early urinary effects | Higher risk of leakage immediately after treatment, usually improves over months | Less impact on continence early; may cause frequency and urgency |
| Bowel effects | Usually minimal — bowel is not irradiated | More bowel irritation, urgency, or rectal bleeding risk |
| Sexual function | Often worsens sharply at first; may partially recover with nerve-sparing surgery | Can worsen more gradually; hormone therapy compounds the effect |
| Practical demands | Hospital stay, catheter, recovery period of 2–4 weeks | Daily hospital visits for 4–7 weeks, but no operation or catheter |
| PSA monitoring after | PSA should become undetectable — clear surveillance signal | PSA falls more slowly and may bounce; interpretation can be less straightforward |
| If cancer returns | Salvage radiotherapy to the prostate bed is a well-established option | Salvage surgery is technically possible but less commonly performed |
When surgery may be the better fit
Robotic prostatectomy often appeals to men who want the cancer physically removed and want a clear post-treatment signal. Once the prostate is gone, PSA should fall to an undetectable level. Many patients find that straightforward to monitor and psychologically settling — the cancer has been removed, and subsequent PSA tests reflect any recurrence directly.
Surgery also tends to suit men who are relatively fit and younger, in whom doctors may lean more seriously towards removing the prostate while it is still confined. If the tumour's position allows nerve-sparing technique, the functional outlook for continence and erections may also be better than feared.
- You prefer certainty — removing the cancer feels right
- You are fit for general anaesthetic
- You prefer one treatment episode rather than weeks of daily visits
- PSA clarity in follow-up matters to you
- Nerve-sparing looks possible based on scan findings
- Salvage radiotherapy being available if needed gives you peace of mind
- You want to avoid a major operation and anaesthetic
- Other health conditions make surgery higher risk
- Bowel symptoms concern you less than urinary leakage
- Maintaining a near-normal routine during treatment is important
- You have easier access to a radiotherapy centre than a robotic surgeon
- Locally advanced disease benefits from combined hormone therapy and radiotherapy
The side effects most men actually experience
Cancer control matters first. Day-to-day function after treatment matters close behind. This is where the choice becomes real — and where honest, specific conversation with your clinician is essential. What follows are the patterns most commonly seen. Your individual risk depends on your age, baseline function, and the specific details of your tumour and treatment plan.
Urinary control
If urinary leakage is your greatest concern, surgery usually carries the heavier early risk. After prostatectomy, almost every man experiences some degree of urinary weakness initially — this is expected and normal. Most men improve progressively over months with pelvic floor exercises and natural healing. A smaller group have longer-lasting leakage that still affects daily life at one year.
Radiotherapy is generally easier on continence in the short term. It can still irritate the bladder, leading to frequency, urgency, or reduced flow, but it is much less likely to cause the same immediate loss of control seen after surgery.
Erectile function
Both treatments can affect erections. Neither should be presented as safe for sexual function, and both deserve honest discussion — not reassurance.
Surgery tends to cause the sharpest early drop. Even with nerve-sparing technique, erections often worsen immediately and may recover only partially. Age, baseline function, vascular health, diabetes, and whether both nerve bundles can be preserved all influence the outcome. Structured penile rehabilitation — starting once healing allows — significantly improves the chances of recovery.
Radiotherapy can look gentler at first, but that is not the whole story. Erectile problems may appear more gradually over months or years, and if hormone therapy is added — which is recommended for intermediate and high-risk disease — libido and erections can be considerably affected. A more accurate framing is this: the timing and trajectory of sexual dysfunction differ between treatments, but the overall burden at five years is broadly similar for many men.
Bowel function
This is where radiotherapy carries the greater risk. Short-term effects can include urgency, loose stools, rectal discomfort, or occasional bleeding. Most men improve once treatment ends, but some experience low-level bowel symptoms that persist. Modern radiotherapy techniques — including IMRT and image guidance — have substantially reduced these risks compared with older methods.
Surgery does not typically cause equivalent bowel problems, because the bowel is not in the treatment field.
Fertility and orgasm
This is often discussed too briefly. After prostatectomy, semen is no longer produced during orgasm — natural conception through intercourse is no longer possible. Radiotherapy can also affect fertility, particularly when combined with hormone therapy. If future fertility matters at all, raise sperm banking before any treatment begins — not after. This applies regardless of age if any chance of future fatherhood is relevant.
Orgasm remains possible after prostatectomy, though it is dry. For many men this is an unexpected change that deserves open conversation before the decision is made, not a surprise after the operation.
Unsure which treatment is right for you?
Mr Sri discusses both options openly at every consultation — including referring to oncology colleagues where radiotherapy is preferred. Same-week appointments available.
How tumour stage, grade, and health shape the options
Not every man is choosing freely between these two treatments. Stage, grade, PSA, MRI findings, and general health all constrain — or sometimes determine — the decision.
For low-risk, fully localised disease, active surveillance may also be a genuine third option for selected men. For cancer that has spread widely, surgery is no longer the primary treatment, and the focus shifts to hormone therapy, radiotherapy in appropriate settings, and systemic treatments.
For locally advanced disease — where cancer has reached beyond the prostate capsule — combined hormone therapy and radiotherapy is often the strongest evidence-based option, and surgery may be offered only at specialist high-volume centres.
Separate what the cancer needs from what you need. Cancer factors — stage, grade group, PSA, MRI findings, lymph node risk — set the clinical parameters. Personal factors — age, fitness, work, caring duties, travel, sexual and urinary priorities — determine which clinically appropriate treatment fits your life. A good decision accounts for both.
Practical UK issues
Both treatments are funded on the NHS, so direct cost is not usually the issue — access is. Not every hospital offers robotic prostatectomy on site, and NICE guidance supports concentrating high-volume robotic surgery at specialist centres. That can be excellent for quality but means some men face longer journeys for a surgical opinion. Radiotherapy is more widely available, though technique and scheduling vary between centres.
Waiting times, transport, work flexibility, and caring responsibilities are not minor details. They can quietly shape whether a catheter and surgical recovery fits your life better than daily outpatient attendance for several weeks — or vice versa. A treatment that looks ideal on paper may be genuinely harder in practice. Real life is part of a good decision.
This is also why hearing from both a urological surgeon and a clinical oncologist before deciding is important. You are entitled to that conversation, and most good teams will arrange it as a matter of course.
Questions to ask your surgeon and oncologist
A strong decision usually follows a strong conversation. If you leave clinic still unsure why one option might suit you better, ask again. Bring a written list. Bring someone with you. Ask the same core questions to both specialists.
- Am I definitely suitable for both treatments — or is one clearly favoured by my scan findings, biopsy grade, or general health?
- What are my specific chances of long-term cure with each option in my risk category?
- Can nerve-sparing surgery be attempted — and if not, why not?
- Would radiotherapy require hormone therapy as well — and for how long?
- What is my personal risk of urinary leakage — not the average risk, but mine, given my age and current function?
- What is my personal risk of erectile dysfunction — given my baseline, age, and whether nerve-sparing is possible?
- How likely are bowel symptoms with radiotherapy — at your specific centre, using your specific technique?
- If the first treatment doesn't achieve control — what is the usual next step for each pathway?
- How many cases does this centre treat each year — for both robotic prostatectomy and prostate radiotherapy?
One standard is worth keeping in mind throughout. If two treatments offer similar cancer outcomes, the decision should be shaped by informed personal preference — not by whichever specialist you happened to meet first, and not by which option required less explanation. That is not too much to ask. It is exactly what good prostate cancer care looks like.